CLYM Stock Overview
A biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Climb Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.25 |
| 52 Week High | US$11.55 |
| 52 Week Low | US$1.73 |
| Beta | -0.25 |
| 1 Month Change | -25.50% |
| 3 Month Change | -56.98% |
| 1 Year Change | -21.60% |
| 3 Year Change | -76.14% |
| 5 Year Change | n/a |
| Change since IPO | -85.85% |
Recent News & Updates
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Sep 23Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Jun 28Recent updates
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Sep 23Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Jun 28Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Feb 01
We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully
Jun 24We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Mar 08We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Nov 18Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09
Aug 15Eliem to discontinue development of lead asset as mid-stage pain trial fails
Aug 02SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating
Jul 11Shareholder Returns
| CLYM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 21.6% | 0.2% | -0.2% |
| 1Y | -21.6% | -4.7% | 25.8% |
Return vs Industry: CLYM underperformed the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: CLYM underperformed the US Market which returned 25.8% over the past year.
Price Volatility
| CLYM volatility | |
|---|---|
| CLYM Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CLYM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CLYM's weekly volatility has decreased from 17% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 10 | Aoife Brennan | eliemtx.com |
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.
Climb Bio, Inc. Fundamentals Summary
| CLYM fundamental statistics | |
|---|---|
| Market cap | US$151.25m |
| Earnings (TTM) | -US$69.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs CLYM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLYM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$69.12m |
| Earnings | -US$69.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.03 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CLYM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 21:56 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Climb Bio, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael DiFiore | Evercore ISI |
| Yatin Suneja | Guggenheim Securities, LLC |
| Marc Goodman | Leerink Partners LLC |